Stuttgart - Delayed Quote EUR

Cyclacel Pharmaceuticals Inc. (UXI.SG)

1.4400 -0.2000 (-12.20%)
At close: April 26 at 8:06 AM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for UXI.SG

Recent News: UXI.SG

View More
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future
Simply Wall St. 2 days ago
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
GlobeNewswire 26 days ago
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
Insider Monkey last month
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire last month
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire last month
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
GlobeNewswire last month
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
GlobeNewswire last month
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
GlobeNewswire 2 months ago
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
GlobeNewswire 2 months ago
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
GlobeNewswire 3 months ago
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
GlobeNewswire 3 months ago
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire 4 months ago
View More

Related Tickers

SLRX Salarius Pharmaceuticals, Inc.
0.4951
+2.93%
 
VRPX Virpax Pharmaceuticals, Inc.
3.1000
+8.01%
 
PHIO Phio Pharmaceuticals Corp.
0.6820
+1.34%
 
IDIA.SW Idorsia Ltd
1.9000
+9.07%
 
CARA Cara Therapeutics, Inc.
0.6843
-2.24%
 
HRTX Heron Therapeutics, Inc.
2.4500
-3.92%
 
XERS Xeris Biopharma Holdings, Inc.
1.7500
+2.94%
 
GRTX Galera Therapeutics, Inc.
0.1861
-10.31%
 
BCLI Brainstorm Cell Therapeutics Inc.
0.5345
+0.47%
 
IRON Disc Medicine, Inc.
27.55
+3.88%